Article

Sartorius Stedim Biotech Acquires Majority Stake in AllPure Technologies

Sartorius Stedim Biotech's acquisition of AllPure Technologies will extends its portfolio for single-use bioprocessing.

Sartorius Stedim Biotech has signed a contract to acquire the majority stake in the US start-up, AllPure Technologies LLC. The privately owned company based in New Oxford, PA, has been in operation for four years, and earned revenue of approximately $3 million in 2013 with 25 employees. AllPure specializes in single-use components for biopharmaceutical applications, such as aseptic sampling techniques. The parties agreed not to disclose any further details of the purchase agreement.

Source: Sartorius Stedim Biotech

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Related Videos
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
© 2025 MJH Life Sciences

All rights reserved.